Cytel, FDA ink research agreement
This article was originally published in The Gray Sheet
Executive Summary
Software and clinical trial design services company Cytel signs a cooperative research and development agreement with FDA's device center to develop a software package to help sponsors and regulators utilize Bayesian statistical methods in clinical trials, the firm announces June 22. FDA encourages Bayesian methods as a way to factor in prior clinical evidence to make new device trials smaller, faster and cheaper, but many physicians are not familiar with the techniques (1"The Gray Sheet" June 22, 2009)